Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate ... Neurocrine Biosciences, Biohaven Pharma, GSK, Roche/Genentech, Takeda, Sanofi, and AbbVie.
Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that Biohaven knowingly submitted or caused false claims to be submitted to Medicaid and other federal health care ...
Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have received an average rating of “Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports.
Biohaven Ltd. (NYSE:BHVN – Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 9,440,000 shares, a decline of ...
Mark J. Alberts, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results